Ignite Creation Date:
2025-12-24 @ 7:09 PM
Ignite Modification Date:
2026-02-25 @ 4:57 PM
Study NCT ID:
NCT02450903
Status:
COMPLETED
Last Update Posted:
2021-03-30
First Post:
2015-05-08
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-Small-Cell Lung Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Non-Small-Cell Lung Cancer | View |
| None | NSCLC | View |
| None | ALK | View |
| None | LDK378 | View |
| None | alectinib | View |
| None | Non-small cell lung carcinoma (NSCLC) | View |
| None | lung cancer | View |
| None | lung adenocarcinoma | View |
| None | Non small cell lung carcinoma | View |
| None | Non small cell lung cancer | View |
| None | Non-small cell lung cancer | View |